Latest news
Microglia Are Not a Shortcut to Alzheimer’s Certainty
Sanofi’s oral TREM2 agonist SAR448851 is moving toward Phase II testing in early Alzheimer’s disease. The mechanism is compelling. The field has already learned that TREM2 biology can disappoint.
Radioligand Therapy Is Building Its Evidence Base. Now Build the Infrastructure.
Tau Is Back. Certainty Is Not.
Alzheimer’s Treatment Moves Home. Risk Does Not.
El Salvador Eliminated Trachoma. The Certificate Is Not The Finish Line.
Gonorrhoea Is Learning To Beat Ceftriaxone. Europe Must Move First.
Why some “resistant” hypertension isn’t resistant at all, and what cardiology might be missing
Desmoid Tumours Are Not Benign to the People Living With Them
Pancreatic Cancer Is Forcing Regulators to Move Faster
When Dementia Takes Speech, Trials Must Catch Up
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.